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ABSTRACT 
Background: Chagas’ disease is an important cause of cardiomyopathy in Latin America. 
We aimed to compare clinical characteristics and outcomes in patients with heart failure and 
reduced ejection fraction (HFrEF) caused by Chagas’ disease, with other etiologies, in the era 
of modern heart failure (HF) therapies. 
 
Methods and Results: This study included 2552 Latin American patients randomized in the 
PARADIGM-HF and ATMOSPHERE trials. The investigator-reported etiology was 
categorized as Chagasic, other non-ischemic and ischemic cardiomyopathy. The outcomes of 
interest included the composite of cardiovascular death or HF hospitalization and its 
components, and death from any cause. Unadjusted and adjusted Cox proportional hazards 
models were performed to compare outcomes by etiology. There were 195 patients with 
Chagasic HFrEF, 1300 other non-ischemic and 1057 ischemic cardiomyopathy. Compared 
with other etiologies, Chagasic patients were more often female, younger and had lower 
prevalence of hypertension, diabetes and renal impairment (but had higher prevalence of 
stroke and pacemaker implantation), and had worse health-related quality of life. The rates of 
the composite outcome were 17.2, 12.5 and 11.4 per 100 person-years for Chagasic, other 
non-ischemic and ischemic patients, respectively - adjusted hazard ratio for Chagasic vs. 
other non-ischemic: 1.49 (95% confidence interval 1.15-1.94, p=0.003) and Chagasic vs. 
ischemic: 1.55 (1.18-2.04, p=0.002). The rates of all-cause mortality were also higher. 
 
Conclusions: Despite younger age, less comorbidity and comprehensive use of conventional 
HF therapies, patients with Chagasic HFrEF continue to have worse quality of life and higher 
hospitalization and mortality rates compared with other etiologies.  
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Clinical Trial Registration: ClinicalTrials.gov number NCT01035255 for PARADIGM-HF 
(https://clinicaltrials.gov/ct2/show/NCT01035255) and NCT00853658 for ATMOSPHERE 
(https://clinicaltrials.gov/ct2/show/NCT00853658). 
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INTRODUCTION 1 
Chagas’ disease, caused by the protozoan Trypanosoma cruzi, is estimated to affect 6 to 7 2 
million people in Latin America and around 300,000 persons in the Unites States of 3 
America.1-10 Indeed, concern about the growing prevalence of Trypanosoma cruzi infection 4 
has led to screening of donations to the blood banks in the USA.11 More recently, cases of 5 
Chagas’ disease have been reported in Europe. 12 Two to three decades after infection, up to 6 
30% of affected individuals exhibit evidence of a chronic cardiomyopathy, ranging from 7 
asymptomatic ECG abnormalities to structural heart disease, with some patients ultimately 8 
developing heart failure with a reduced ejection fraction (HFrEF).1-10 Despite the high 9 
prevalence of Chagas’ disease little is known about the morbidity and mortality in patients 10 
with HFrEF caused by Chagas’ disease, compared with other etiologies, especially in the 11 
modern era of heart failure (HF) therapies.13-21 We pooled the two largest and most recent 12 
trials in HFrEF, the Prospective comparison of ARNI with ACEI to Determine Impact on 13 
Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) and the Aliskiren 14 
trial to Minimize OutcomeS in Patients with Heart failure trial (ATMOSPHERE) to look 15 
further into investigator-reported Chagasic heart failure in Latin America.22, 23  16 
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METHODS 1 
Study population 2 
This study consisted of 2552 Latin American patients with HFrEF randomized in the 3 
PARADIGM-HF and ATMOSPHERE trials. The design and primary results of both studies 4 
have been published.22, 23 Briefly, in PARADIGM-HF patients had New York Heart 5 
Association (NYHA) class II-IV symptoms, a left ventricular ejection fraction (LVEF) ≤40% 6 
(changed to ≤35% by amendment) and an elevated plasma natriuretic peptide level (B-type 7 
natriuretic peptide [BNP] ≥150 pg/ml or N-terminal pro-BNP [NT-proBNP] ≥600 pg/ml). 8 
Patients with lower natriuretic peptide levels (BNP ≥100 pg/ml or NT-proBNP ≥400 pg/ml) 9 
were eligible if they had been hospitalized for HF within 12 months. Patients were required to 10 
receive an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker 11 
(ARB) (equivalent to enalapril ≥10 mg daily), along with a stable dose of a beta-blocker 12 
(unless contraindicated) and a mineralocorticoid receptor antagonist (MRA) (if indicated) for 13 
at least 4 weeks before screening. In ATMOSPHERE patients had NYHA class II-IV 14 
symptoms HF with a reduced LVEF (≤35%) and an elevated plasma natriuretic peptide level 15 
(same criteria as in PARADIGM-HF). Patients were required to be treated with an ACE 16 
inhibitor (equivalent to enalapril ≥10 mg daily), a stable dose of a beta-blocker (unless 17 
contraindicated) for at least 4 weeks before screening and could be treated with a MRA if felt 18 
to be indicated by the investigator. Both trials used a composite of cardiovascular death or HF 19 
hospitalization as the primary outcome. Both trials were approved by the ethics committee in 20 
each study center. All patients gave written informed consent. 21 
 22 
Primary etiology of heart failure 23 
The primary HF etiology was collected at the screening visit using a similar, structured, case 24 
report form in both trials. We used this information to categorize the patients into three 25 
8 
 
mutually exclusive subgroups, i.e. investigator-reported Chagas’ disease, other non-ischemic 1 
cardiomyopathy and ischemic cardiomyopathy. 2 
 3 
Study outcomes  4 
The outcomes of interest in this study included a composite of cardiovascular death or first 5 
HF hospitalization and its components, as well as death from any cause. We also examined 6 
the two major modes of cardiovascular death i.e.  sudden death and pump failure death. 7 
 8 
Statistical analyses 9 
Baseline characteristics were summarized as means with standard deviations for continuous 10 
variables and numbers with percentages for categorical variables. Baseline characteristics 11 
were compared across HF etiology categories using ANOVA for continuous variables with 12 
Bonferroni correction for multiple comparisons and the chi-square test for categorical 13 
variables. The Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score24 14 
and NT-proBNP were not normally distributed and therefore were summarized as medians 15 
with the first and  third quartile (Q1 to Q3), and analyzed using Kruskal-Wallis test with 16 
Dunn's test and Bonferroni correction for multiple comparisons. Event rates for each outcome 17 
according to HF etiology were calculated per 100 patient-years of follow-up. The 18 
proportional hazards (Cox) regression analysis was used to calculate the hazard ratio (HR) for 19 
each outcome with the comparisons of Chagas’ disease vs. non-ischemic cardiomyopathy, 20 
and Chagas’ disease vs. ischemic cardiomyopathy. The proportional hazards regression 21 
analyses were also performed with adjustment for treatment assignment, age, sex, LVEF, 22 
NYHA class and NT-proBNP (log transformed) to account for the confounding. Within-trial 23 
clustering was taken into consideration with the use of shared frailty models. A two-sided p-24 
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value <0.05 was considered statistically significant. All statistical analyses were performed 1 
using Stata version 14 (Stata Corp, College Station, TX, USA).   2 
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RESULTS 1 
Overall, 195 patients (7.6 % of the total) were reported to have Chagasic cardiomyopathy, 2 
1300 (51%) another type of non-ischemic cardiomyopathy and 1057 (41%) ischemic HFrEF. 3 
The largest number of Chagas’ patients were enrolled in Brazil (n=112; accounting for 22.7% 4 
of all patients randomized in that country), followed by Argentina (n=60; 7.2%) and 5 
Colombia (n=16; 5.2%) [see Supplemental Table S1]. 6 
 7 
Baseline characteristics:   The baseline characteristics of patients with Chagasic HFrEF 8 
compared to those with other non-ischemic cardiomyopathy and ischemic cardiomyopathy 9 
are shown in Table 1. 10 
 11 
Notable differences included the younger age of individuals with Chagasic cardiomyopathy, 12 
their lower systolic blood pressure, lower body mass index and lower prevalence of 13 
hypertension and diabetes, compared with patients in the other etiology subgroups. 14 
Individuals with Chagasic HFrEF were more likely to be female and have a history of stroke 15 
and renal impairment than in the other etiology subgroups (especially compared to patients 16 
with other non-ischemic HFrEF). Right bundle branch block was much more common in 17 
patients with Chagasic cardiomyopathy compared to patients with other causes of non-18 
ischemic and ischemic HFrEF, while left bundle branch block was less common in patients 19 
with Chagas’ disease compared to the other groups.  20 
 21 
Patients with Chagasic HFrEF were much more likely than other patients to have a history of 22 
pacemaker implantation. Beta-blockers were used less often in patients with Chagasic 23 
cardiomyopathy compared to other types of HFrEF but anticoagulant and, especially, 24 
amiodarone treatment was used more frequently. 25 
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 1 
Patients with Chagasic HFrEF reported significantly worse health-related quality of life, as 2 
evaluated using the KCCQ with median (Q1 to Q3) values of 85 [72-94], 87 [74-96] and 82 3 
[70-92] in patients with ischemic, other non-ischemic and Chagasic cardiomyopathy. 4 
 5 
Clinical outcomes:   The rates of the primary composite outcome, its components and all-6 
cause death are shown in Table 2 and Figure 1. Patients with Chagasic HFrEF had a higher 7 
unadjusted and adjusted risk of the primary outcome compared with each of the other 8 
etiologic categories, with the adjusted risk approximately 50% greater. The adjusted risk of 9 
both cardiovascular and all-cause death was approximately 40% greater in patients with 10 
Chagasic cardiomyopathy than in patients with ischemic HFrEF. The adjusted risk of all-11 
cause death was also higher than in patients with non-ischemic HFrEF, although the risk of 12 
cardiovascular death was not statistically significantly higher.  13 
We also examined the two main modes of cardiovascular death (Table 2). The risk of sudden 14 
death did not differ significantly by etiology, although in Chagasic patients this mode of 15 
death was relatively less common than in patients with ischemic cardiomyopathy and 16 
relatively more common than in patients with other causes of non-ischemic cardiomyopathy 17 
(but these trends were not statistically significant). Conversely, pump failure death was more 18 
common in Chagasic patients, especially when compared with ischemic cardiomyopathy 19 
patients.  20 
Patients with a Chagasic etiology had a substantially elevated risk (60-80% higher) of HF 21 
hospitalization compared with each of the other etiologic categories. In sensitivity analyses, 22 
additional adjustment for right and left bundle branch block did not materially alter the 23 
difference in risk between patients with Chagas’ disease and those in the other groups (data 24 
not shown).  25 
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DISCUSSION 1 
Approximately 8% of patients enrolled in ATMOSPHERE and PARADIGM-HF in Latin 2 
America had HFrEF attributed to Chagas’ disease. Although higher rates have been reported 3 
in some registers from more endemic regions the proportion in our study is consistent with 4 
two prior studies from the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en 5 
Argentina (GESICA) where were 9.3% and 5.7%, respectively, of patients had HFrEF due to 6 
Chagas’ disease.25, 26 Our cases also showed a geographic distribution consistent with the 7 
known epidemiology of Chagas’ cardiomyopathy.27 8 
  9 
Although several prior studies have compared individuals with Chagasic HFrEF to others 10 
with ischemic or non-ischemic cardiomyopathy (but not both concomitantly), these have been 11 
mainly single-center reports of often highly-selected cohorts (e.g. transplant referrals) usually 12 
markedly under-treated by contemporary standards.12-20, 28 These prior reports included 13 
between 25 and 246 patients with Chagas’ cardiomyopathy and 50 to 454 patients in the 14 
comparator group, usually did not report detailed characterization of participants (e.g. in 15 
relation to prior history and biomarkers) and often did not adjust for differences in a 16 
multivariable analysis when comparing outcomes across etiologic groups.13-21, 28 17 
  18 
Despite these differences, it is possible to make some comparisons with our findings. In both 19 
the prior studies and in ours, Chagasic patients were notable by their younger age and lower 20 
preponderance of males (especially when compared to patients with ischemic HFrEF). The 21 
high prevalence of right bundle branch block, prior pacemaker implantation and amiodarone 22 
use are also characteristic features of patients with Chagasic cardiomyopathy.29 23 
 24 
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Our cohort, recruited according to standardized trial inclusion and exclusion criteria, does, 1 
however, highlight other striking differences. The low prevalence of diabetes and history of 2 
hypertension, compared to patients with other non-ischemic and ischemic HFrEF is striking 3 
and the latter is consistent with the much lower systolic blood pressure in the Chagasic group.  4 
Similarly, the markedly higher prevalence of prior stroke (in the absence of a substantially 5 
higher prevalence of atrial fibrillation) is consistent with concerns about high risk of 6 
thromboembolism in patients with Chagasic cardiomyopathy (and reflected in the higher use 7 
of anticoagulant therapy in these individuals).30 8 
 9 
We noted worse renal function in Chagasic patients, compared with the others, despite 10 
younger age and less diabetes and hypertension. Why this finding has not been previously 11 
reported, and the reason for it is uncertain, the greater use of MRA in Chagasic patients and 12 
lower systolic blood pressure may have played a role. 13 
 14 
One finding which, notably, was not significantly different, with respect to etiology, was 15 
baseline NT-proBNP level (although this was numerically highest in the Chagasic patients). 16 
As NT-proBNP is the single most powerful prognostic variable in heart failure, it is 17 
interesting that outcomes were so much worse for patients with Chagas’ disease. Why 18 
prognosis is worse is, therefore, not clear. Immune or inflammatory mechanisms might be 19 
relevant or other biological or non-biological issues might be important. For example, 20 
Chagas’ disease is more prevalent in more socioeconomically deprived populations and this 21 
may influence health and outcomes in a variety of ways. 22 
 23 
Although the protocol for both PARADIGM-HF and ATMOSPHERE required beta-blockers 24 
to be used in all patients unless not tolerated or contraindicated, fewer patients with Chagasic 25 
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HFrEF (85%) were treated with an agent from this class than in the other non-ischemic 1 
patients (91%) or in the ischemic group (93%).  Nevertheless, this is a much higher use than 2 
reported in most prior studies in Chagasic patients where the rate has been typically around 3 
40%, usually because of concerns about sinoatrial and conducting-system disease.12-20 4 
Resting heart rate was notably lower (65 beats per minute) in our Chagasic patients, 5 
compared with the other non-ischemic group (72 beats per minute) and ischemic group (70 6 
beats per minute), despite the different rate of beta-blocker use.  However, amiodarone use 7 
(43%) was very common in Chagasic patients (compared with 11% of patients in the other 8 
non-ischemic group and 9% of those in the ischemic group).  In addition, 39% of Chagasic 9 
patients were also receiving a digitalis glycoside (compared with 42% of patients in the other 10 
non-ischemic group and 27% of patients in the ischemic group).  While the use of all three of 11 
these drugs might be concerning, especially in a condition associated with sinoatrial and 12 
conduction system disease, 30% of Chagasic patients had a pacemaker and a few more had 13 
CRT or an ICD. 14 
 15 
Patients with HFrEF due to Chagas’ disease also differed from the others in terms of clinical 16 
outcomes. Specifically, their adjusted risk of death (cardiovascular or all-cause) was about 17 
40% higher than in the other etiologic groups and risk of heart failure hospitalization 60-80% 18 
greater (despite the higher risk of death). These findings are notable in two ways. Firstly, they 19 
demonstrate the markedly higher risk in patients with Chagasic cardiomyopathy once HFrEF 20 
develops. In the recent Evaluation of the Use of Antiparasital Drug (Benznidazole) in the 21 
Treatment of Chronic Chagas' Disease trial (BENEFIT), where among patients of a similar 22 
average age, only about a quarter of patients were in NYHA functional class II or greater and 23 
only 17% of patients had a LVEF <40%, the annual mortality rate was around 3%.31 In our 24 
patients it was 13%. However, the excess risk related to Chagas’ disease in our cohort was 25 
15 
 
much less than suggested in prior studies.13-21 Whether this is due to the historical nature of 1 
prior studies (with less comprehensive therapy), less complete adjustment for other 2 
prognostic variables, smaller and less comprehensive comparator groups or some other factor 3 
or factors is unknown. The most recent study to compare outcomes between patients with 4 
Chagasic cardiomyopathy and other patients was undertaken among Latin American 5 
Immigrants in the Los Angeles area.32 Although that study reported a more than 4-fold higher 6 
risk of death or transplantation among Chagasic patients compared to patients with other 7 
types of non-ischemic cardiomyopathy, it included a total of 135 patients, of which only 25 8 
had Chagasic cardiomyopathy (and there were only a total of 20 events). 9 
We were also able to examine the two principal modes of cardiovascular death in the three 10 
etiologic groups studied. This analysis showed that the excess mortality risk in Chagasic 11 
patients was due to pump failure rather than sudden death (especially compared to patients 12 
with an ischemic etiology). While this finding might seem surprising in a condition widely 13 
considered to be highly arrhythmogenic, it is consistent with the view that modern 14 
pharmacologic therapy, by reducing the risk of sudden death, may have resulted in pump 15 
failure death becoming the major mode of death in Chagas’ disease.33 We have already 16 
highlighted the much greater use of beta-blockers in the current compared with prior reports. 17 
The potential role of amiodarone in preventing sudden death in Chagas’s cardiomyopathy is 18 
more controversial. 19 
 20 
As with any study of this type there are limitations. This was a post hoc analysis. HFrEF 21 
etiology was reported by investigators and not verified in any way; however, the 22 
characteristics of the patients in the different etiologic subgroups were consistent with what 23 
would be expected suggesting valid categorization by investigators. The total number of 24 
patients with Chagasic HFrEF was relatively small but similar or larger than in other studies 25 
16 
 
comparing etiologies. The protocol required patients to be treated with a beta-blocker unless 1 
contraindicated or not tolerated and patients had to tolerate enalapril 10mg twice daily and 2 
sacubitril/valsartan 97/103mg twice daily before randomization, resulting in selection of 3 
patients who could tolerate these different treatments. We did not have data on 4 
socioeconomic status. 5 
 6 
CONCLUSIONS  7 
Despite their younger age, less comorbidity and comprehensive use of conventional 8 
pharmacological therapies for HFrEF, patients with Chagasic HFrEF continue to have worse 9 
quality of life and higher hospitalization and mortality rates compared to those with HFrEF 10 
due to other non-ischemic and ischemic causes.  11 
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FIGURE LEGENDS 
Figure 1. Kaplan-Meier curves for clinical outcomes according to heart failure etiology (Latin 
American patients in combined PARADIGM-HF and ATMOSPHERE datasets). 
Kaplan-Meier estimates of the probability of the death from cardiovascular causes or first 
hospitalization for heart failure (Panel A), death from cardiovascular causes (Panel B), first 
hospitalization for heart failure (Panel C), and death from any cause (Panel D).  
CV = cardiovascular; HF=heart failure. 
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Figure 1. Kaplan-Meier curves for clinical outcomes according to heart failure etiology (Latin American patients in combined 
PARADIGM-HF and ATMOSPHERE datasets).
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Kaplan-Meier estimates of the probability of the death from cardiovascular causes or first 
hospitalization for heart failure (Panel A), death from cardiovascular causes (Panel B), first 
hospitalization for heart failure (Panel C), and death from any cause (Panel D).  
CV = cardiovascular; HF=heart failure. 
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Table 1. Baseline characteristics in patients with Chagasic heart failure compared to 
those with non-ischemic cardiomyopathy and those with ischemic cardiomyopathy in 
Latin America in the combined datasets of PARADIGM-HF and ATMOSPHERE. 
 
Chagasic  Other non-
ischemic  
Ischemic  P value  
 
N=195  N=1300 N=1057 Chagasic 
vs. Other 
non-
ischemic 
Chagasic 
vs. 
Ischemic 
Age -years 59.6±10.7 61.1±12.5 65.8±10.1 0.291 <0.0001 
Male sex -n (%) 129 (66.2) 897 (69.0) 828 (78.3) 0.424 <0.0001 
Race -n (%)  
  
<0.0001 <0.0001 
White 107 (54.9)  554 (42.6) 449 (42.5)   
Black 34 (17.4)  147 (11.3) 46 (4.4)   
Asian 0 (0.0)  0 (0.0) 2 (0.2)   
Other 54 (27.7)  599 (46.1) 560 (53.0)   
BMI - kg/m2 26.0±4.6 27.6±5.2 27.4±4.5 <0.0001 0.001 
Blood pressure -mmHg  
  
  
Systolic 111.4±12.5 120.3±15.9 120.7±15.0 <0.0001 <0.0001 
Diastolic 71.4±8.8 74.3±10.7 72.9±10.1 0.001 0.206 
Heart rate -beats/min 65.5±10.3 72.0±12.0 70.2±11.3 <0.0001 <0.0001 
LVEF -% 28.5±6.2 27.1±6.3 28.5±6.1 0.015 0.999 
NYHA class -n (%)  
  
0.103 0.070 
   I 11 (5.7)  80 (6.2) 47 (4.5)   
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   II 170 (87.6)  1054 (81.1) 868 (82.2)   
  III 13 (6.7)  165 (12.7) 140 (13.3)   
  IV 0 (0.0)  1 (0.1) 1 (0.1)   
Medical history -n (%)  
  
  
Current smoker 14 (7.2) 110 (8.5) 74 (7.0) 0.545 0.929 
Previous HF 
hospitalization 
100 (51.3) 727 (55.9) 525 (49.7) 0.224 0.679 
Myocardial infarction 1 (0.5) 35 (2.7) 748 (70.8) 0.064 <0.0001 
Angina 4 (2.1) 35 (2.7) 223 (21.1) 0.600 <0.0001 
CABG or PCI 1 (0.5) 28 (2.2) 396 (37.5) 0.121 <0.0001 
Hypertension 85 (43.6) 874 (67.2) 739 (69.9) <0.0001 <0.0001 
Diabetes 15 (7.7) 290 (22.3) 341 (32.3) <0.0001 <0.0001 
Atrial fibrillation 63 (32.3) 380 (29.2) 182 (17.2) 0.380 <0.0001 
Stroke 27 (13.8) 56 (4.3) 88 (8.3) <0.0001 0.014 
Medication/devices -n (%)  
  
  
Digitalis 75 (38.5) 543 (41.8) 284 (26.9) 0.382 0.001 
Diuretics 158 (81.0) 1086 (83.5) 785 (74.3) 0.381 0.044 
ACE inhibitor or ARB 113 (100.0) 699 (99.4) 616 (99.8) 0.422 0.668 
Beta-blocker 166 (85.1) 1187 (91.3) 984 (93.1) 0.006 <0.0001 
MRA  133 (68.2) 763 (58.7) 539 (51.0) 0.011 <0.0001 
Antiplatelet  61 (31.3) 576 (44.3) 763 (72.2) 0.001 <0.0001 
Anticoagulant 54 (27.7) 285 (21.9) 161 (15.2) 0.073 <0.0001 
Amiodarone 80 (41.0) 150 (11.5) 100 (9.5) <0.0001 <0.0001 
Pacemaker 59 (30.3) 77 (5.9) 83 (7.9) <0.0001 <0.0001 
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CRT 5 (2.6) 23 (1.8) 15 (1.4) 0.445 0.241 
ICD 15 (7.7) 40 (3.1) 48 (4.5) 0.001 0.064 
ECG findings -n (%)  
  
  
Atrial fibrillation 37 (19.0) 283 (21.8) 114 (10.8) 0.367 0.001 
Left bundle branch block 23 (11.8) 402 (31.0) 228 (21.7) <0.0001 0.002 
Right bundle branch 
block  
46 (23.6) 92 (7.1) 96 (9.1) <0.0001 <0.0001 
Q waves 7 (3.6) 70 (5.4) 311 (29.5) 0.288 <0.0001 
left ventricular 
hypertrophy 
7 (3.6) 334 (25.8) 187 (17.8) <0.0001 <0.0001 
Laboratory measures  
  
  
eGFR -ml/min/1.73m2 69.2±19.8 75.1±28.0 70.1±21.8 0.006 0.999 
eGFR <60 
ml/min/1.73m2 -n (%) 
67 (34.4) 334 (25.7) 345 (32.6) 0.011 0.639 
Serum creatinine -mg/dl 1.10±0.28 1.03±0.30 1.08±0.30 0.011 0.999 
NT-proBNP -pg/ml 1753  
[793-3247] 
1539  
[840-3367] 
1486 
 [808-2973] 
0.999 0.583 
Symptoms, signs and 
HRQL -n (%) 
     
Dyspnea on effort 176 (90.7) 1113 (85.6) 921 (87.2) 0.054 0.171 
Dyspnea at rest 4 (2.1) 19 (1.5) 22 (2.1) 0.526 0.985 
Orthopnea 8 (4.1) 113 (8.7) 98 (9.3) 0.030 0.018 
Paroxysmal nocturnal 
dyspnea 
4 (2.1) 40 (3.1) 49 (4.6) 0.435 0.101 
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Fatigue 71 (36.6) 419 (32.2) 387 (36.6) 0.227 0.989 
Edema 23 (11.9) 198 (15.2) 185 (17.5) 0.217 0.052 
Jugular venous distention 24 (12.4) 192 (14.8) 168 (15.9) 0.376 0.209 
Third heart sound 9 (4.6) 105 (8.1) 61 (5.8) 0.092 0.527 
Rales 9 (4.6) 64 (4.9) 86 (8.1) 0.864 0.090 
KCCQ clinical summary 
score* 
82 [70-92] 87 [ 74-96] 85 [72-94] 0.006 0.255 
 
Plus-minus values are mean ±SD. NT-proBNP and KCCQ clinical summary score are 
summarized as median [the first quartile to the third quartile]. 
ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; BMI = body 
mass index; CABG = coronary artery bypass grafting; CRT = Cardiac resynchronization 
therapy; ECG = electrocardiogram; eGFR = estimated glomerular filtration rate; HF = heart 
failure; HRQL = health-related quality of life; ICD =Implantable cardioverter defibrillator; 
KCCQ = Kansas City Cardiomyopathy Questionnaire; LVEF = left ventricular ejection 
fraction; MRA = mineralocorticoid receptor antagonist; NT-proBNP = N terminal pro-B type 
natriuretic peptide; NYHA = New York Heart Association; PCI=percutaneous coronary 
intervention. 
*Values of the KCCQ clinical summary score (on a scale from 0 to 100, with higher scores 
indicating better health-related quality of life) were available for 1101 patients with non-
ischemic cardiomyopathy, for 848 patients with ischemic cardiomyopathy, and for 189 
patients with Chagas disease.  
29 
 
Table 2. Outcomes according to etiology in Latin America in the combined datasets of PARADIGM-HF and ATMOSPHERE. 
 
Event, 
number (%) 
Annual rate, 
per 100 person-years (95% CI) 
Unadjusted HR (95% CI)* Adjusted HR (95% CI)*† 
 
Chagasic 
(N=195) 
Other non-
ischemic 
(N=1300) 
Ischemic 
(N=1057) 
Chagas Other non-
ischemic 
Ischemic Chagasic vs. 
Other non-
ischemic 
Chagasic vs. 
Ischemic 
Chagasic vs. 
Other non-
ischemic 
Chagasic vs. 
Ischemic 
CV death or  
HFH  
 
67 (34.4) 364 (28.0) 264 (25.0) 17.2 
(13.6-21.9) 
12.5 
(11.3-13.8) 
11.4 
(10.1-12.9) 
1.37 
(1.06-1.78), 
p=0.017 
1.48 
(1.13-1.94), 
p=0.004 
1.49 
(1.15-1.94), 
p=0.003 
1.55 
(1.18-2.04), 
p=0.002 
CV death 46 (23.6) 287 (22.1) 199 (18.8) 10.7 
(8.0-14.3) 
9.2 
(8.2-10.4) 
8.1 
(7.1-9.4) 
1.17 
(0.86-1.60), 
p=0.314 
1.32 
(0.96-1.82), 
p=0.092 
1.30 
(0.95-1.78), 
p=0.097 
1.44 
(1.04-2.00), 
p=0.027 
HFH 37 (19.0) 175 (13.5) 115 (10.9) 9.5 
(6.9-13.1) 
6.0 
(5.2-7.0) 
5.0 
(4.1-6.0) 
1.56 
(1.10-2.23), 
p=0.014 
1.86 
(1.28-2.69), 
p=0.001 
1.64 
(1.15-2.35), 
p=0.006 
1.83 
(1.25-2.67), 
p=0.002 
30 
 
All-cause death 57 (29.2) 336 (25.9) 251 (23.7) 13.3 
(10.2-17.2) 
10.8 
(9.7-12.0) 
10.3 
(9.1-11.6) 
1.24 
(0.94-1.64), 
p=0.131 
1.30 
(0.97-1.73), 
p=0.077 
1.36 
(1.02-1.80), 
p=0.035 
1.43 
(1.06-1.91), 
p=0.017 
Sudden death 14 (7.2) 101 (7.8) 96 (9.1) 3.3 
(1.9-5.5) 
3.2 
(2.7-3.9) 
3.9 
(3.2-4.8) 
1.00 
(0.57-1.75), 
p=0.99 
0.81 
(0.46-1.43), 
p=0.47 
1.11 
(0.63-1.94), 
p=0.73 
0.89 
(0.51-1.58), 
p=0.70 
Pump failure 
death 
16 (8.2) 83 (6.4) 41 (3.9) 3.7 
(2.3-6.1) 
2.7 
(2.2-3.3) 
1.7 
(1.2-2.3) 
1.40 
(0.82-2.40), 
p=0.22 
2.25 
(1.26-4.02), 
p=0.01 
1.69 
(0.98-2.91), 
p=0.06 
2.52 
(1.40-4.56), 
p=0.002 
 
CI = confidence interval; CV = cardiovascular; HFH = heart failure hospitalization; HR = hazard ratio. 
*Hazard ratios for combined data were adjusted for within-trial clustering. 
†Adjusted covariates: treatment group, age, sex, LVEF, NYHA class and log 2 base NT-proBNP. 
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CLINICAL PERSPECTIVES 
What is new?  
Patients with HFrEF due to Chagas’ disease continue to have worse quality of life and higher 
hospitalization and mortality rates, compared with other etiologies, despite their younger age, 
less comorbidity and comprehensive use of conventional HF therapies. 
 
What are the clinical implications?  
Better understanding of the mechanism and natural history of Chagasic heart failure is needed 
in the future studies to identify strategies for improving its prognosis. 
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